logo

Idera Pharmaceuticals, Inc. (IDRA)



Trade IDRA now with
  Date
  Headline
6/12/2018 7:31:40 AM Idera Pharma: Phase 2 Trial Of IMO-8400 Did Not Meet Primary Endpoint Of Statistically Significant Reduction Of CDASI
6/12/2018 7:30:17 AM Idera Pharmaceuticals Reports Results From Phase 2 Trial Of IMO-8400 In Dermatomyositis
6/4/2018 7:36:27 AM Idera Pharma Presents Clinical Data From ILLUMINATE-204 Trial Of Combination Of Tilsotolimod And Ipilimumab
5/9/2018 7:19:10 AM Idera Pharma Q1 Loss Applicable To Stockholders $20.1 Mln Or $0.10/Shr Vs Loss $15.1 Mln Or $0.10/Shr Last Year
4/17/2018 7:09:01 AM Idera Pharma Presents Pre-Clinical Data Demonstrating Potential For IMO-2125 In Combination With Checkpoint Inhibitors
4/16/2018 7:11:13 AM Idera Pharma Enters Into A Clinical Development Support Agreement With Pillar Partners Foundation
4/10/2018 7:33:07 AM BioCryst And Idera Reschedule Meetings To Vote On Proposed Merger To July 10, 2018
4/2/2018 2:59:44 PM RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals
4/2/2018 8:11:22 AM Idera Files Definitive Proxy Statement In Connection With Pending Merger With BioCryst
3/7/2018 7:33:37 AM Idera Pharma Q4 Loss Applicable To Stockholders $14.9 Mln Or $0.08/Shr Vs Income $0.8 Mln Or $0.01/Shr Last Year
3/1/2018 7:22:24 AM Idera Pharma Announces Launch Of Global Phase 3 Trial Evaluating IMO-2125 In Combination With Ipilimumab
2/27/2018 8:16:17 AM BioCryst And Idera File Preliminary Proxy Statement And Investor Presentation In Connection With Pending Merger
1/5/2018 7:03:11 AM Idera Pharma Provides 2018 Update And Outlook
11/29/2017 7:33:00 AM FDA Grants Fast Track Designation For Idera’ IMO-2125 In Combination With Ipilimumab
11/15/2017 5:33:12 PM Wedbush Is Lowering Idera Pharmaceuticals, Inc. (IDRA) FY18 Rev. Estimate To 0.0 M From 0.8 M
11/15/2017 5:33:02 PM Wedbush Is Cutting Idera Pharmaceuticals, Inc. (IDRA) Q4 18 Rev. Estimate To 0.0 M From 0.2 M
11/15/2017 5:32:52 PM Wedbush Is Cutting Idera Pharmaceuticals, Inc. (IDRA) Q3 18 Rev. Estimate To 0.0 M From 0.2 M